The antibiotic mithramycin A (MMA) is a potential DNMT1 inhibitor, which could reduce the CpG island methylation of SLIT2 and TIMP-3 genes and could cause the degradation of DNMT1 in lung cancer cells. The gene discussed is DNMT1; the disease is lung carcinoma.